Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia.

Leukemia - 1 May 2005

Passamonti F, Pietra D, Rumi E, Arcaini L, Della Porta M G, Malcovati L, Pascutto C, Lazzarino M, Cazzola M

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cohort Studies
Share to GPI-Linked Proteins
Share to Isoantigens
Share to Membrane Glycoproteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polycythemia Vera

Share to Receptors, Cell Surface

Share to RNA, Messenger

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 15744342
DOI: 10.1038/sj.leu.2403700

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia.PMID 15744342Read ↗

PRV-1 mRNA expression discriminates two types of essential thrombocythemiaSemantic proximity Read ↗

[New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].Semantic proximity Read ↗

Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study.Semantic proximity Read ↗

Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.Semantic proximity Read ↗

Management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.Semantic proximity Read ↗

Impact of ELN clinical signs and symptoms on the thrombotic risk in Polycythemia Vera patients treated with front-line hydroxyureaSemantic proximity Read ↗

[Survival and prognosis of patients with polycythemia vera: a study of 816 patients in a single Chinese center].Semantic proximity Read ↗

The advantages and risks of ruxolitinib for the treatment of polycythemia vera.Semantic proximity Read ↗

Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations.Semantic proximity Read ↗

Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera.Semantic proximity Read ↗

Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.